首页> 外文期刊>Pharmaceutics >Design and In Vivo Pharmacokinetic Evaluation of Triamcinolone Acetonide Microcrystals-Loaded PLGA Microsphere for Increased Drug Retention in Knees after Intra-Articular Injection
【24h】

Design and In Vivo Pharmacokinetic Evaluation of Triamcinolone Acetonide Microcrystals-Loaded PLGA Microsphere for Increased Drug Retention in Knees after Intra-Articular Injection

机译:曲安奈德微粉载PLGA微球的设计和体内药代动力学评价可提高关节腔内注射后膝关节的药物保留能力

获取原文
           

摘要

A novel polymeric microsphere (MS) containing micronized triamcinolone acetonide (TA) in a crystalline state was structured to provide extended drug retention in joints after intra-articular (IA) injection. Microcrystals with a median diameter of 1.7 μm were prepared by ultra-sonication method, and incorporated into poly(lactic- co -glycolic acid)/poly(lactic acid) (PLGA/PLA) MSs using spray-drying technique. Cross-sectional observation and X-ray diffraction analysis showed that drug microcrystals were evenly embedded in the MSs, with a distinctive crystalline nature of TA. In vitro drug release from the novel MSs was markedly decelerated compared to those from the marketed crystalline suspension (Triam inj. ? ), or even 7.2 μm-sized TA crystals-loaded MSs. The novel system offered prolonged drug retention in rat joints, providing quantifiable TA remains over 28 days. Whereas, over 95% of IA TA was removed from joints within seven days, after injection of the marketed product. Systemic exposure of the steroidal compound was drastically decreased with the MSs, with 50% systemic exposure compared to that with the marketed product. The novel MS was physicochemically stable, with no changes in drug crystallinity and release profile over 12 months. Therefore, the TA microcrystals-loaded MS is expected to be beneficial in patients especially with osteoarthritis, with reduced IA dosing frequency.
机译:新型的聚合物微球(MS)含有微粉化的曲安奈德(TA)处于结晶状态,其结构可在关节内(IA)注射后在关节中提供延长的药物保留。通过超声法制备中值直径为1.7μm的微晶,并使用喷雾干燥技术将其掺入聚(乳酸-共-乙醇酸)/聚(乳酸)(PLGA / PLA)MS中。横截面观察和X射线衍射分析表明,药物微晶均匀地嵌入MS中,具有TA的独特结晶性质。与从市场上出售的晶体悬浮液(Triam inj。),甚至7.2μm大小的TA晶体负载的MS相比,新型MS的体外药物释放明显降低。该新型系统可延长大鼠关节中的药物滞留时间,可在28天内提供可量化的TA残留量。而注射市售产品后的7天内,超过95%的IA TA从关节中去除。 MS可使类固醇化合物的全身暴露量大大降低,与市售产品相比,全身暴露量<50%。新型MS理化稳定,在12个月内药物结晶度和释放曲线均无变化。因此,预期载有TA微晶的MS对IA给药频率降低的患者尤其是骨关节炎患者有益。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号